Clinical Trial Update: The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tegaserod for irritable bowel syndrome with constipation examined patterns of small bowel flow; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome Constipation Predominant

Drugs mentioned

• Zelnorm (tegaserod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Constipation Predominant, Irritable Bowel Syndrome (IBS-C) | Phase 3 | Status: TERMINATED